Quantum BioPharma wins FDA IND clearance for Lucid-MS Phase 2 trial in progressive MS
QNTM•Liquidity reported as of March 31, 2026
Quantum BioPharma reported more than USD 10 million in cash, digital assets, and liquid investments as of March 31, 2026.
FDA clearance enables Lucid-MS Phase 2 trial
Quantum BioPharma said it secured FDA clearance for its IND, enabling a Phase 2 trial of Lucid-MS in progressive multiple sclerosis.
The study is planned as a randomized, double-blind, placebo-controlled trial, with site selection underway and enrollment expected to start soon.
